Cargando…

Clinical characteristics of myasthenia gravis (MG) patients developing other autoimmune diseases after thymectomy from one single center cohort

BACKGROUND: Myasthenia gravis (MG) patients are reported to have a high risk of other autoimmune diseases (ADs), and thymectomy may increase the risk further. A cohort of MG patients in which thymectomy was performed were investigated to analyze the prevalence, types and features of the new onset AD...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Wenxin, He, Jing, Yu, Hanbo, Sun, Yaoguang, Wu, Qingjun, Jiao, Peng, Ma, Chao, Huang, Chuan, Li, Donghang, Tong, Hongfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834700/
https://www.ncbi.nlm.nih.gov/pubmed/36419347
http://dx.doi.org/10.1111/1759-7714.14723
_version_ 1784868518675611648
author Tian, Wenxin
He, Jing
Yu, Hanbo
Sun, Yaoguang
Wu, Qingjun
Jiao, Peng
Ma, Chao
Huang, Chuan
Li, Donghang
Tong, Hongfeng
author_facet Tian, Wenxin
He, Jing
Yu, Hanbo
Sun, Yaoguang
Wu, Qingjun
Jiao, Peng
Ma, Chao
Huang, Chuan
Li, Donghang
Tong, Hongfeng
author_sort Tian, Wenxin
collection PubMed
description BACKGROUND: Myasthenia gravis (MG) patients are reported to have a high risk of other autoimmune diseases (ADs), and thymectomy may increase the risk further. A cohort of MG patients in which thymectomy was performed were investigated to analyze the prevalence, types and features of the new onset ADs. METHODS: Consecutive patients with MG who underwent thymectomy at Beijing Hospital between January 2012 and August 2021 were retrospectively enrolled. Patients with a postoperative follow‐up period shorter than a year or incomplete clinical records were excluded. Clinical and follow‐up data were collected. Statistical analyses were performed using SPSS version 22.0. RESULTS: A total of 445 patients were included in this study. The median follow‐up period was 72 months (range, 12–135 months). A total of 63 (14.2%) MG patients had concurrent ADs. The incidence rate was higher than the background prevalence of population (5%), and also higher than that of a former Chinese MG cohort (11.6%). A total of 47 patients (10.6%) were diagnosed with ADs before thymectomy, and 19 (4.3%) developed a new AD after thymectomy. The most common types of new onset ADs after thymectomy were Hashimoto's thyroiditis and rheumatoid arthritis (RA), which were different from those before thymectomy (hyperthyroidism and Hashimoto's thyroiditis). The incidence rate of new onset RA (1.35%) was higher than the frequency of RA before thymectomy (0.45%), and also higher than the incidence rate in a Chinese MG cohort (0.5%). There was a higher proportion of female patients (p = 0.026) with postoperative ADs. A younger age at operation may increase the risk of nonthymoma MG patients (p = 0.040) developing ADs. The postoperative treatment effect of MG was similar between patients with and without new onset ADs (p > 0.05). CONCLUSIONS: We observed a higher incidence rate of autoimmune diseases, especially rheumatoid arthritis, in MG patients after thymectomy. The most common types of ADs after thymectomy were different from those before thymectomy. New onset ADs tended to occur in female and young nonthymoma MG patients. The postoperative effect of MG was not related with the new occurrence of ADs.
format Online
Article
Text
id pubmed-9834700
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-98347002023-01-17 Clinical characteristics of myasthenia gravis (MG) patients developing other autoimmune diseases after thymectomy from one single center cohort Tian, Wenxin He, Jing Yu, Hanbo Sun, Yaoguang Wu, Qingjun Jiao, Peng Ma, Chao Huang, Chuan Li, Donghang Tong, Hongfeng Thorac Cancer Original Articles BACKGROUND: Myasthenia gravis (MG) patients are reported to have a high risk of other autoimmune diseases (ADs), and thymectomy may increase the risk further. A cohort of MG patients in which thymectomy was performed were investigated to analyze the prevalence, types and features of the new onset ADs. METHODS: Consecutive patients with MG who underwent thymectomy at Beijing Hospital between January 2012 and August 2021 were retrospectively enrolled. Patients with a postoperative follow‐up period shorter than a year or incomplete clinical records were excluded. Clinical and follow‐up data were collected. Statistical analyses were performed using SPSS version 22.0. RESULTS: A total of 445 patients were included in this study. The median follow‐up period was 72 months (range, 12–135 months). A total of 63 (14.2%) MG patients had concurrent ADs. The incidence rate was higher than the background prevalence of population (5%), and also higher than that of a former Chinese MG cohort (11.6%). A total of 47 patients (10.6%) were diagnosed with ADs before thymectomy, and 19 (4.3%) developed a new AD after thymectomy. The most common types of new onset ADs after thymectomy were Hashimoto's thyroiditis and rheumatoid arthritis (RA), which were different from those before thymectomy (hyperthyroidism and Hashimoto's thyroiditis). The incidence rate of new onset RA (1.35%) was higher than the frequency of RA before thymectomy (0.45%), and also higher than the incidence rate in a Chinese MG cohort (0.5%). There was a higher proportion of female patients (p = 0.026) with postoperative ADs. A younger age at operation may increase the risk of nonthymoma MG patients (p = 0.040) developing ADs. The postoperative treatment effect of MG was similar between patients with and without new onset ADs (p > 0.05). CONCLUSIONS: We observed a higher incidence rate of autoimmune diseases, especially rheumatoid arthritis, in MG patients after thymectomy. The most common types of ADs after thymectomy were different from those before thymectomy. New onset ADs tended to occur in female and young nonthymoma MG patients. The postoperative effect of MG was not related with the new occurrence of ADs. John Wiley & Sons Australia, Ltd 2022-11-23 /pmc/articles/PMC9834700/ /pubmed/36419347 http://dx.doi.org/10.1111/1759-7714.14723 Text en © 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Tian, Wenxin
He, Jing
Yu, Hanbo
Sun, Yaoguang
Wu, Qingjun
Jiao, Peng
Ma, Chao
Huang, Chuan
Li, Donghang
Tong, Hongfeng
Clinical characteristics of myasthenia gravis (MG) patients developing other autoimmune diseases after thymectomy from one single center cohort
title Clinical characteristics of myasthenia gravis (MG) patients developing other autoimmune diseases after thymectomy from one single center cohort
title_full Clinical characteristics of myasthenia gravis (MG) patients developing other autoimmune diseases after thymectomy from one single center cohort
title_fullStr Clinical characteristics of myasthenia gravis (MG) patients developing other autoimmune diseases after thymectomy from one single center cohort
title_full_unstemmed Clinical characteristics of myasthenia gravis (MG) patients developing other autoimmune diseases after thymectomy from one single center cohort
title_short Clinical characteristics of myasthenia gravis (MG) patients developing other autoimmune diseases after thymectomy from one single center cohort
title_sort clinical characteristics of myasthenia gravis (mg) patients developing other autoimmune diseases after thymectomy from one single center cohort
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834700/
https://www.ncbi.nlm.nih.gov/pubmed/36419347
http://dx.doi.org/10.1111/1759-7714.14723
work_keys_str_mv AT tianwenxin clinicalcharacteristicsofmyastheniagravismgpatientsdevelopingotherautoimmunediseasesafterthymectomyfromonesinglecentercohort
AT hejing clinicalcharacteristicsofmyastheniagravismgpatientsdevelopingotherautoimmunediseasesafterthymectomyfromonesinglecentercohort
AT yuhanbo clinicalcharacteristicsofmyastheniagravismgpatientsdevelopingotherautoimmunediseasesafterthymectomyfromonesinglecentercohort
AT sunyaoguang clinicalcharacteristicsofmyastheniagravismgpatientsdevelopingotherautoimmunediseasesafterthymectomyfromonesinglecentercohort
AT wuqingjun clinicalcharacteristicsofmyastheniagravismgpatientsdevelopingotherautoimmunediseasesafterthymectomyfromonesinglecentercohort
AT jiaopeng clinicalcharacteristicsofmyastheniagravismgpatientsdevelopingotherautoimmunediseasesafterthymectomyfromonesinglecentercohort
AT machao clinicalcharacteristicsofmyastheniagravismgpatientsdevelopingotherautoimmunediseasesafterthymectomyfromonesinglecentercohort
AT huangchuan clinicalcharacteristicsofmyastheniagravismgpatientsdevelopingotherautoimmunediseasesafterthymectomyfromonesinglecentercohort
AT lidonghang clinicalcharacteristicsofmyastheniagravismgpatientsdevelopingotherautoimmunediseasesafterthymectomyfromonesinglecentercohort
AT tonghongfeng clinicalcharacteristicsofmyastheniagravismgpatientsdevelopingotherautoimmunediseasesafterthymectomyfromonesinglecentercohort